Signaling pathways in intestinal homeostasis and colorectal cancer: KRAS at centre stage
C Ternet, C Kiel - Cell Communication and Signaling, 2021 - Springer
The intestinal epithelium acts as a physical barrier that separates the intestinal microbiota
from the host and is critical for preserving intestinal homeostasis. The barrier is formed by …
from the host and is critical for preserving intestinal homeostasis. The barrier is formed by …
CXCL3: a key player in tumor microenvironment and inflammatory diseases
Y Bao, C Tong, X **ong - Life Sciences, 2024 - Elsevier
Abstract CXCL3 (CXC Motif Chemokine 3), a member of the CXC chemokine subfamily,
operates as a potent chemoattractant for neutrophils, thereby orchestrating the recruitment …
operates as a potent chemoattractant for neutrophils, thereby orchestrating the recruitment …
KRAS signaling enriched triple negative breast cancer is associated with favorable tumor immune microenvironment and better survival
KRAS signaling is associated with cancer progression in several cancers. Upregulation of
KRAS signaling is often seen in cancers that harbor high KRAS mutation rate, such as …
KRAS signaling is often seen in cancers that harbor high KRAS mutation rate, such as …
[HTML][HTML] Relevance of regulatory T cells during colorectal cancer development
JE Olguín, I Medina-Andrade, T Rodríguez… - Cancers, 2020 - mdpi.com
In recent years, there has been a significant increase in the study of own and foreign human
factors favoring the development of different types of cancer, including genetic and …
factors favoring the development of different types of cancer, including genetic and …
Microsatellite instability in cancer: a novel landscape for diagnostic and therapeutic approach
H Yamamoto, Y Watanabe, T Maehata, K Imai… - Archives of toxicology, 2020 - Springer
Defective DNA mismatch repair creates a strong mutator phenotype, recognized as
microsatellite instability (MSI). Various next-generation sequencing-based methods for …
microsatellite instability (MSI). Various next-generation sequencing-based methods for …
Immuno-genomic classification of colorectal cancer organoids reveals cancer cells with intrinsic immunogenic properties associated with patient survival
Background The intrinsic immuno-ge7nomic characteristics of colorectal cancer cells that
affect tumor biology and shape the tumor immune microenvironment (TIM) are unclear …
affect tumor biology and shape the tumor immune microenvironment (TIM) are unclear …
Inflammatory signaling in genomically instable cancers
F Talens, MATM Van Vugt - Cell Cycle, 2019 - Taylor & Francis
Recent studies have shown that genomic instability in tumor cells leads to activation of
inflammatory signaling through the cGAS/STING pathway. In this review, we describe …
inflammatory signaling through the cGAS/STING pathway. In this review, we describe …
Research progress of preoperative FPR, FAR or AFR in patients with colorectal cancer
C Chen, Y Liu, P Han, B Cui - Cancer management and research, 2021 - Taylor & Francis
Research has confirmed that plasma albumin (Alb), prealbumin (PA) and fibrinogen (Fib)
are involved in regulating the occurrence and development of various tumors. Their levels in …
are involved in regulating the occurrence and development of various tumors. Their levels in …
Resistance to immunotherapy: mechanisms and means for overcoming
Immune checkpoint blockade transformed cancer therapy during the last decade. However,
durable responses remain uncommon, early and late relapses occur over the course of …
durable responses remain uncommon, early and late relapses occur over the course of …
A non-randomised open-label exploratory 'window of opportunity'study of TG02 treatment in patients with locally advanced primary and recurrent RAS mutant …
S Roth, KC Wilson, RG Ramsay, C Mitchell… - Heliyon, 2025 - cell.com
Background TG02 is a peptide-based cancer vaccine eliciting immune responses to
oncogenic codon 12/13 RAS mutations. This phase 1 clinical trial (NCT02933944) assessed …
oncogenic codon 12/13 RAS mutations. This phase 1 clinical trial (NCT02933944) assessed …